Literature DB >> 2821181

Humoral and cellular immunity to varicella-zoster virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea-pig.

A M Arvin1, S M Solem, C M Koropchak, E Kinney-Thomas, S G Paryani.   

Abstract

Strain 2 guinea-pigs were inoculated with infectious varicella-zoster virus (VZV) or with immunoaffinity-purified proteins of VZV. Monoclonal antibodies to the VZV gpI (90,000/58,000 complex) and to a non-glycosylated protein, p170, were used to prepare the polypeptide antigens. Humoral and cell-mediated immune responses to the infectious virus were compared with those elicited by the gpI and p170 proteins. Both VZV IgG antibody production and T lymphocyte proliferation to VZV were detected after immunization with infectious VZV and with VZV proteins. The antibody and T lymphocyte responses waned after protein immunization in comparison with the responses induced by infectious VZV but were detected again immediately after reimmunization with gpI or p170.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2821181     DOI： 10.1099/0022-1317-68-9-2449

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  11 in total

1.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Antigens of infectious laryngotracheitis herpesvirus defined by monoclonal antibodies.

Authors:  J J York; S Sonza; M R Brandon; K J Fahey
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 3.  VZV infection of keratinocytes: production of cell-free infectious virions in vivo.

Authors:  Michael D Gershon; Anne A Gershon
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

4.  Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization.

Authors:  C M Koropchak; S M Solem; P S Diaz; A M Arvin
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV.

Authors:  A R Hayward
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

6.  Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs.

Authors:  A R Hayward; R Burger; R Scheper; A M Arvin
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge.

Authors:  C Sabella; P W Lowry; G M Abbruzzi; C M Koropchak; P R Kinchington; M Sadegh-Zadeh; J Hay; W T Ruyechan; A M Arvin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.

Authors:  T C Heineman; B L Connelly; N Bourne; L R Stanberry; J Cohen
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Infected peripheral blood mononuclear cells transmit latent varicella zoster virus infection to the guinea pig enteric nervous system.

Authors:  Lin Gan; Mingli Wang; Jason J Chen; Michael D Gershon; Anne A Gershon
Journal:  J Neurovirol       Date:  2014-06-26       Impact factor: 3.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.